Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialThomas L Holland, Robert C. Hyzy, Mamta K. Jain et al.|The Lancet Respiratory Medicine|2022Cited by 127
Current clinical spectrum of common variable immunodeficiency in Spain: The multicentric nationwide GTEM-SEMI-CVID registryMarta Dafne Cabañero-Navalón, Pedro Moral, Víctor García-Bustos et al.|Frontiers in Immunology|2022Cited by 36
The burden of post-acute COVID-19 symptoms in a multinational network cohort analysisKristin Kostka, Annika M. Jödicke, Elena Roel et al.|Nature Communications|2023Cited by 24
The impact of immune dysregulation on the risk of malignancy in common variable immunodeficiency: insights from a multicenter studyMarta Dafne Cabañero-Navalón, Pedro Moral, Víctor García-Bustos et al.|Frontiers in Immunology|2024Cited by 11
Characterization of long-term patient-reported symptoms of COVID-19: an analysis of social media dataJuan M. Banda, Daniel Prieto‐Alhambra, N.A. Adderley et al.|medRxiv|2021Cited by 8